The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Two-year follow-up results from EPCORE CLL-1: epcoritamab monotherapy in Richter’s transformation
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses two-year follow-up results from arm 2A of the Phase Ib/II EPCORE CLL-1 trial (NCT04623541) of epcoritamab monotherapy in patients with Richter’s transformation. Dr Eichhorst reports a promising median progression-free survival and manageable safety profile. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The EPCORE CLL-1 study is a Phase II trial evaluating the bispecific antibody directed against CD20 and CD3 in patients with Richter’s transformation. So there were patients allowed to enter when they had no prior treatment for their Richter’s transformation as well as patients who had already had prior treatment for the Richter’s transformation. And overall what the study is showing is that the median PFS was quite promising, in particular in the patients not being previously treated; however, we see how challenging it is to treat patients with previous Richter’s transformation...
The EPCORE CLL-1 study is a Phase II trial evaluating the bispecific antibody directed against CD20 and CD3 in patients with Richter’s transformation. So there were patients allowed to enter when they had no prior treatment for their Richter’s transformation as well as patients who had already had prior treatment for the Richter’s transformation. And overall what the study is showing is that the median PFS was quite promising, in particular in the patients not being previously treated; however, we see how challenging it is to treat patients with previous Richter’s transformation. With respect to the safety profile in that study, there was, I think, only one CTC grade 3 ICANS and a few more of CTC grade 3 CRS, but with more corticosteroids being applied in patients with Richter’s transformation, as well as for CLL, the potential additional dose we can use in the ramp-up period. It seems that also bispecifics are tolerated by the patients. And so it’s a really interesting other option for patients with this difficult-to-treat disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
